

SYSTEMATIC REVIEW AND META-ANALYSES

Siddharth Singh, Section Editor

Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression



Lorenzo A. Orci,^{*,‡,a} Marco Sanduzzi-Zamparelli,^{§,||,a} Berta Caballol,^{§,a} Victor Sapena,[§] Nicola Colucci,^{*,¶} Ferran Torres,^{#,**} Jordi Bruix,[§] María Reig,^{§,b} and Christian Toso^{*,‡,b}

^{*}Division of Abdominal and Transplantation Surgery, Department of Surgery, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; [‡]Hepato-pancreato-biliary Centre, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; [§]BCLC Group, Liver Unit, Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain; ^{||}Department of Clinical Medicine and Surgery, Gastroenterology Unit, University of Naples Federico II, Naples, Italy; [¶]Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; [#]Medical Statistics Core Facility, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain; and ^{**}Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) may be a risk factor for hepatocellular carcinoma (HCC), but the extent of this association still needs to be addressed. Pooled incidence rates of HCC across the disease spectrum of NAFLD have never been estimated by meta-analysis.

METHODS: In this systematic review, we searched Web of Science, Embase, PubMed, and the Cochrane Library from January 1, 1950 through July 30, 2020. We included studies reporting on HCC incidence in patients with NAFLD. The main outcomes were pooled HCC incidences in patients with NAFLD at distinct severity stages. Summary estimates were calculated with random-effects models. Sensitivity analyses and meta-regression analyses were carried out to address heterogeneity.

RESULTS: We included 18 studies involving 470,404 patients. In patients with NAFLD at a stage earlier than cirrhosis, the incidence rate of HCC was 0.03 per 100 person-years (95% confidence interval [CI], 0.01–0.07; $I^2 = 98\%$). In patients with cirrhosis, the incidence rate was 3.78 per 100 person-years (95% CI, 2.47–5.78; $I^2 = 93\%$). Patients with cirrhosis undergoing regular screening for HCC had an incidence rate of 4.62 per 100 person-years (95% CI, 2.77–7.72; $I^2 = 77\%$).

CONCLUSIONS: Patients with NAFLD-related cirrhosis have a risk of developing HCC similar to that reported for patients with cirrhosis from other etiologies. Evidence documenting the risk in patients with nonalcoholic steatohepatitis or simple steatosis is limited, but the incidence of HCC in these populations may lie below thresholds used to recommend a screening. Well-designed prospective studies in these subpopulations are needed. The protocol for this systematic review is registered in the Prospero database (registration number CRD42018092861).

Keywords: Hepatocellular Carcinoma; Incidence; Meta-analysis; Nonalcoholic Fatty Liver Disease.

Epidemiologic data indicate an alarming rise in the global prevalence of NAFLD, which has now become one of the most common forms of chronic liver disease. Predictions suggest that the burden of NAFLD will grow further in the next decades.¹ These epidemiologic trends have made NAFLD-induced cirrhosis a leading cause of HCC.^{2–4} The global incidence of HCC related to NAFLD is projected to increase from 47% in 2016 to 130% in 2030.⁵ However, because NAFLD encompasses a wide spectrum of disease, the precise extent of the association between NAFLD and HCC remains unclear.^{6,7} Although the development of cirrhosis appears to be a major driver of hepatocarcinogenesis (independently

from the underlying liver disease), the risk of developing HCC in other subpopulations of patients with NAFLD needs to be better addressed.⁸ Some evidence indicates

^aAuthors share co-first authorship. ^bAuthors share co-senior authorship.

Abbreviations used in this paper: CI, confidence interval; HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PY, person-year.

Most current article

© 2022 AGA Institute. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1542-3565

<https://doi.org/10.1016/j.cgh.2021.05.002>

that patients with NAFLD may develop HCC at stages earlier than cirrhosis.^{9,10} However, those studies did not take into consideration whether patients were enrolled in HCC surveillance programs.

In chronic hepatitis B for instance, there is some evidence to support that screening for HCC is cost-effective in high-risk carriers without cirrhosis, when the rate of HCC exceeds 0.2% per year.^{11,12} As for NAFLD, European practice guidelines recommend regular surveillance for HCC in patients with cirrhosis when the annual rate of HCC exceeds 1.5% per year.¹³ The American Association for the Study of Liver Disease cautiously suggests that the latter threshold may also be applicable to patients with non-cirrhotic NAFLD.¹² However, as of today, it is unknown whether non-cirrhotic patients with NAFLD truly carry a risk of developing HCC that lies above either of these thresholds. Therefore, the benefit of surveillance in non-cirrhotic NAFLD patients remains uncertain.

Two previous systematic reviews by White et al¹⁴ and Stine et al¹⁵ have looked at the association between NAFLD and HCC. Despite their seminal work in 2012, White et al did not provide quantitative pooling of the results by meta-analysis. More importantly, a large amount of newer evidence has been published since 2012. Among other findings, the meta-analysis by Stine et al reported 2.61 times higher incidence of HCC in non-cirrhotic NAFLD in comparison with patients with liver disease of other etiology. Although this is an important indication of the depth of association between HCC and NAFLD, the result does not inform health care stakeholders about the absolute incidence of HCC in the NAFLD population. Furthermore, neither of the 2 above-mentioned systematic reviews specifically addressed the impact of screening, which is a key public health issue. Our group also published the results of a conference-related qualitative literature review in 2019,¹⁶ but we believed that a more thorough systematic review was needed, especially considering that the public health awareness with regard to the NAFLD epidemic grows bigger, and that several important studies have been published in the meantime. In the current systematic review and meta-analysis, we aimed to estimate the pooled incidence rates of HCC across the spectrum of NAFLD and to evaluate the impact of surveillance on the detection rate.

Methods

Search Strategy and Selection Criteria

The protocol for this systematic review is registered in the Prospero database (registration number CRD42018092861). The reviewing process was conducted according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. We searched Web of Science, Embase, PubMed, and the Cochrane Library from January 1, 1950 through July 30, 2020 by formulating keyword searches. The exact query

What You Need to Know

Background

The risk of hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD) has been reported in various studies. This systematic review and meta-analysis evaluated the pooled incidence of HCC in various populations of patients with NAFLD.

Findings

On the basis of the current results, the incidence of HCC in patients with NAFLD at a stage earlier than cirrhosis is 0.03 per 100 person-years (95% CI, 0.01–0.07). In patients with cirrhosis, the rate is 3.78 per 100 person-years (95% CI, 2.47–5.78). Patients with cirrhosis undergoing regular screening for HCC have an incidence rate of 4.62 per 100 person-years (95% CI, 2.77–7.72). Results were highly heterogeneous.

Implications for patient care

Patients with nonalcoholic fatty liver disease (NAFLD)-related cirrhosis have a risk of developing hepatocellular carcinoma (HCC) similar to that reported for patients with cirrhosis from other etiology. Evidence documenting the risk in patients with nonalcoholic steatohepatitis (NASH) or simple steatosis is limited and highly heterogeneous.

formulated in Web of Science was as follows: "(TS=(nonalcoholic fatty liver OR nafld OR nbnc OR naf OR non alcoholic fatty liver disease OR non-alcoholic fatty liver OR non-alcoholic fatty liver disease OR nonalcoholic fatty liver disease OR non-alcoholic steatohepatitis OR nonalcoholic steatohepatitis OR non-alcoholic steato-hepatitis OR non-alcoholic steato hepatitis OR non alcoholic steatohepatitis OR non alcoholic steato-hepatitis OR non alcoholic steato hepatitis OR nonalcoholic steato-hepatitis OR nonalcoholic steato-hepatitis OR fatty liver disease OR fatty liver OR non-alcoholic steatosis OR nonalcoholic steatosis OR non alcoholic steatosis OR non viral hepatitis OR non-viral hepatitis OR non b non c OR non-b non-c OR nash OR steato-hepatitis OR steatohepatitis OR liver steatosis OR steatosis OR metabolic syndrome OR liver fat infiltration) AND TS=(liver cell carcinoma OR hepatic carcinoma OR liver cell carcinoma OR hepatic cell carcinoma OR hepatocarcinoma OR hepatocellular carcinoma OR hepatoma OR liver carcinoma OR primary liver carcinoma OR malignant hepatoma OR hcc OR carcinoma of the liver))". Keyword combinations used in other databases are reported in the [Supplementary Material](#). Duplicate reports were eliminated by scrutinizing the list of aggregated reports. In addition, we manually scanned the reference list of previously published systematic reviews^{14,15} and that of articles retrieved from the literature search.

Two reviewers (LO, BC) independently selected potentially relevant studies on the basis of title and abstract reading. Full-text articles were then gathered and assessed for eligibility by the same 2 independent reviewers. In case of discrepancies, consensus was reached after discussion with senior authors (CT, MR). To be eligible, studies had to report within a study population of patients diagnosed with NAFLD (all other etiologies including cryptogenic cirrhosis were excluded), the number of incident HCC cases over time, or the cumulative incidence. We excluded studies where patients were already diagnosed with HCC when entering the study; studies not reporting the follow-up period; studies assessing the recurrence of HCC after liver resection, transplantation, or ablative therapies; studies that did not specifically report on HCC; and studies that did not specify whether and how alcohol intake was accounted for. We also excluded conference abstracts, letters, and editorials. We did not search for unpublished reports or the grey literature.

Outcome of Interest

The outcome of interest was the pooled incidence rate of HCC, as estimated in patients at distinct stages of NAFLD severity and according to their clinical management. In other words, the incidence rates of HCC were calculated for (1) patients with non-cirrhotic NAFLD, (2) patients with NAFLD-induced cirrhosis, (3) patients with NAFLD-induced cirrhosis enrolled in a dedicated screening program, and (4) those not undergoing regular surveillance.

Data Analysis

Two authors extracted data by using a pre-established form. In addition to the usual bibliometric variables, information on the following variables was also collected: duration of inclusion; study design; methods used to diagnose NAFLD and HCC; median follow-up; percentage of patients with simple steatosis, NASH, and cirrhosis; number of incident HCC cases; enrollment (and structure of) a systematic HCC screening program; age; sex; body mass index; presence of diabetes and dyslipidemia; alanine aminotransferase and aspartate aminotransferase serum levels; Model for End-Stage Liver Disease score; and platelet count.

Critical appraisal was done independently by 2 reviewers (LO, BC) using the National Institutes of Health Quality Assessment Tool for observational cohort and cross-sectional studies.¹⁷ Briefly, this tool checks for the presence of 14 core quality components of observational studies, including population sampling, definition of both the exposure and the outcome, timeframe for the exposure to exert an effect on the outcome, presence of the exposure variable (NAFLD) before the outcome (HCC), blinding of outcome assessors, and losses to follow-up.

On the basis of these components, each study is rated as good, fair, or poor in quality (indicating low, moderate, and high risk of bias, respectively). When means and standard deviations were not reported, we estimated them from medians and percentiles.¹⁸

The number of cases and the person-years (PYs), calculated as the product of the total number at risk and the follow-up from individual studies, were used to compute the pooled number of incident HCC cases per 100 PYs of follow-up, and their 95% confidence intervals (CIs) were estimated using the random-effects model described by Der Simonian and Laird¹⁹ with the meta-rate command of R. Heterogeneity was evaluated by means of the I^2 statistic, and values of I^2 of 25%, 50%, and 75% were considered to indicate low, moderate, and high heterogeneity, respectively.²⁰ A χ^2 heterogeneity test was performed to evaluate the statistical significance of the lack of homogeneity, considering $P < .100$ as threshold.²¹

A funnel plot was constructed to assess publication bias. Heterogeneity was investigated through several approaches. First, we conducted sensitivity analyses, looking at the impact of factors such as (1) the diagnostic tool used to establish the diagnosis of NAFLD, (2) the epidemiologic design, (3) the methodological quality, and (4) the geographical location of the included studies. We also performed leave-one-out analyses to evaluate whether a single study could have a marked impact on overall heterogeneity. Next, we used random-effects meta-regression models to evaluate the impact of baseline covariates on the calculated heterogeneity. Whenever I^2 was greater than 50%, date of publication (≤ 2010 versus > 2010), study duration, age, sex, presence of diabetes, Model for End-Stage Liver Disease score, platelet count, and aspartate aminotransferase and alanine aminotransferase blood levels were included as covariates.

Between-reviewer agreement in terms of methodological quality and decision to include studies was assessed by means of Kendall and kappa coefficients, respectively. All statistical analyses were performed using RStudio Team 2018 software (RStudio: Integrated Development for R; RStudio, Inc, Boston, MA), and the level of significance was set at the two-sided 5%. Meta-regression was performed using the `metareg` command of R.

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had access to the study data and reviewed and approved the final manuscript.

Results

Literature Search and Critical Appraisal

After duplicate removal, our literature searches yielded 10,263 articles. We screened 139 potentially

relevant reports, reviewed 89 articles in full-text, and finally included 18 studies in the analysis.²²⁻³⁹ Between-reviewer agreement for the inclusion process was 0.92 (95% CI, 0.84–0.99), as assessed by the kappa coefficient. Details of the inclusion process and reasons for exclusion are shown in Figure 1. The characteristics of the included studies are summarized in Table 1. Reasons for excluding the 71 out of the 89 selected articles are reported in the Supplementary Table 1.

The 18 studies enrolled 470,404 patients with a diagnosis of NAFLD. Overall, 20% of the whole population were women. However, when we excluded the study by Kanwal et al,³⁰ which analyzed data of 296,707 U.S. military veteran personnel, the proportion of women rose to 55%. The diagnosis of NAFLD and/or NASH was based on liver histology in 5 studies,^{25,27,29,36,39} whereas other reports used a combination of liver imaging and blood level of aminotransferases^{22,24,28,33,35} or ultrasound only.^{23,31,32} Of note, the study by Adams et al²² reported separate analyses for a subgroup of patients with histologically proven NASH lesions.

There was variability in terms of the presence of NASH and NAFLD-induced cirrhosis across the included studies (Supplementary Table 2). As for cancer screening, patients were enrolled in dedicated surveillance programs for HCC in 10 studies, using repeated ultrasound imaging,^{25,31,35} combined ultrasound and

blood level of alpha-fetoprotein,^{23,27,33,39,40} computed tomography,²⁴ or a combination of these approaches.³⁷ The presence of conditions that are commonly associated with NAFLD (such as diabetes, hypertension, and obesity) is reported in Table 2.

Critical appraisal, as assessed by the National Institutes of Health Quality Assessment Tool (Supplementary Table 3), indicated that one study had high risk of bias,²³ 11 moderate risk,^{26-35,39} and 6 low risk.^{22,24,25,36-38} Between-reviewer concordance was 0.72 (95% CI, 0.41–0.99), as assessed by the Kendall coefficient.

Quantitative Synthesis of the Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease

When gathering studies that included at least some patients with cirrhosis, the estimated pooled incidence rate of HCC was 2.39 per 100 PYs (95% CI, 1.40–4.08; $I^2 = 93%$; heterogeneity test $P < .01$; Figure 2A). To estimate more specifically the risk of HCC carried by patients with NAFLD-related cirrhosis, we restricted the analysis to studies that only included patients with established cirrhosis.^{24,27-29,33,35,38} In these studies, the pooled incidence of HCC was 3.78 per 100 PYs (95% CI,




Figure 1. PRISMA flow diagram of study selection. HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.

Table 1. Characteristics of Studies

First author	Year of publication	Country	Study design	Period of inclusion	Screening type	NAFLD-patients with cirrhosis (%)
Hui	2003	Australia	Prospective	NA	No screening	100
Adams	2005	USA	Retrospective	1980–2000	No screening	NA
Ekstedt	2006	Sweden	NA	1988–1993	No screening	4.5
Hashimoto	2009	Japan	Prospective	1990–2007	US + AFP	35.8
Yatsuji	2009	Japan	Prospective	1990–2006	US + AFP	100
Ascha	2010	USA	Retrospective	2003–2007	Others	100
Bhala	2011	International	Prospective	1984–2006	US	52.2
Arase	2012	Japan	Retrospective	1994–2007	US + AFP	NA
Kawamura	2012	Japan	Retrospective	1997–2010	US	NA
Kodama	2013	Japan	Retrospective	1990–2010	US + AFP	100
Önnerhag	2014	Sweden	Prospective	1974–1992	No screening	25
Hsiang	2015	New Zealand	Retrospective	2000–2011	No screening	100
Kim	2017	South Korea	Retrospective	2004–2005	No screening	NA
Lee	2017	Taiwan	Retrospective	1998–2012	No screening	NA
Marot	2017	Switzerland	Prospective	1995–2014	US	100
Kanwal	2018	USA	Retrospective	2004–2008	NA	0.5
Alexander	2019	International	Retrospective	Before 2016	NA	0
Yang	2020	USA	Retrospective	2006–2015	NA	100

AFP, alpha-fetoprotein; NA, not available; NAFLD, nonalcoholic fatty liver disease; US, ultrasound.

2.47–5.78; $I^2 = 81\%$; heterogeneity test $P < .01$; [Figure 2B](#)). The pooled incidence of HCC in patients with cirrhosis enrolled in a HCC screening program^{24,27,33,35} was 4.62 per 100 PYs (95% CI, 2.77–7.72; $I^2 = 77\%$; heterogeneity test $P < .01$; [Figure 2C](#)). In contrast, the pooled incidence rate of HCC was markedly lower (2.35 per 100 PYs) when we pooled studies that included patients not undergoing regular surveillance (95% CI, 0.99–5.61; $I^2 = 56\%$; heterogeneity test $P < .01$; [Figure 2D](#)). When looking at those 3 studies^{22,30,37} reporting the incidence of HCC in patients with non-cirrhotic NAFLD, we found that the incidence rate of HCC in non-cirrhotic patients was 0.03 per 100 PYs (95% CI, 0.01–0.07; $I^2 = 98\%$; heterogeneity test $P = .02$; [Figure 2E](#)).

Investigating Heterogeneity

Next, because between-study heterogeneity was very high in most of our meta-analyses, we carried out several sensitivity analyses ([Supplementary Table 4](#)), restricting data aggregation according to potential sources of heterogeneity. Despite modifying the calculated effect sizes, these factors did not allow us to remove residual heterogeneity. Meta-regression analyses ([Figure 3](#)) were performed considering the duration of patient inclusion

in the individual studies, patient age, proportion of men, percentage of patients with diabetes, and date of publication. The meta-regression considering the date of publication revealed a coefficient $P = .04$ ([Supplementary Table 5](#)). However, even after allowing for this factor, global heterogeneity (considering all the remaining confounders) still remained very high ($I^2 = 94\%$). Other variables evaluated by meta-regression did not reach statistical significance ([Figure 3, Supplementary Table 5](#)). We finally performed a leave-one-out sensitivity analysis ([Supplementary Table 6](#)) on those studies reporting on the incidence of HCC in patients with cirrhosis, but this strategy only marginally reduced heterogeneity ($I^2 > 90\%$). We did not find evidence of publication bias, as assessed by using a funnel plot ([Supplementary Figure 1](#)).

Discussion

In this systematic review and meta-analysis, we provide a comprehensive assessment of the incidence of HCC in various subpopulations of patients with NAFLD, taking into account the impact of HCC screening. When looking at studies that only included patients with cirrhosis, the incidence rate of HCC was 3.78 per 100 PYs (95% CI, 2.47–5.78), a finding of similar magnitude to

Table 2. Patient Characteristics

First author	Year of publication	Age, y (mean \pm SD)	Gender (male-%)	Obesity (%)	BMI, kg/m ² (mean \pm SD)	Diabetes (%)	Hypertension (%)	Dyslipidemia (%)
Hui	2003	52.6 \pm 13.6	30	70	32.0 \pm 5.1	65	48	30
Adams	2005	49 \pm 15	49	71	33.5 \pm 6.5	26	36	23
Ekstedt	2006	61 \pm 11	70	33	29.1 \pm 4.7	57	94	40
Hashimoto	2009	NA	NA	NA	NA	NA	NA	NA
Yatsuji	2009	62.7 \pm 13.2	43	24	27.8 \pm 5.4	68	47	34
Ascha	2010	56 \pm 7.6 ^a	44.1	NA	34.7 \pm 5.3 ^a	73.1	NA	NA
Bhala	2011	54.7 \pm 11.6	39.7	NA	32.8 \pm NA	50.6	44.1	NA
Arase	2012	62.5 \pm 9.5	75	NA	25.1 \pm 2.6	NA	17.4	NA
Kawamura	2012	52.7 \pm 46.7 ^a	87.7	NA	28.6 \pm 21.6 ^a	8.2	12.9	NA
Kodama	2013	63.5 \pm 12.9	32	74	27.7 \pm 5.3	58	54	42
Önnerhag	2014	47.5 \pm 7.3	72.2	NA	27.1 \pm 12.4 ^a	41.7	50	33.3
Hsiang	2015	63 \pm 12	50	NA	NA	NA	NA	NA
Kim	2017	50.1 \pm 9.7	71.1	NA	25.7 \pm 2.6	16.2	32.3	NA
Lee	2017	52.9 \pm 16.9 ^a	52.6	NA	NA	37	55.9	23.3
Marot	2017	63 \pm 20 ^a	51	NA	31 \pm 1.5 ^a	73	NA	NA
Kanwal	2018	55.4 \pm NA	94.4	NA	30.7 \pm NA	29.9	70.2	NA
Alexander	2019	55.8 (13.6)	52.7	NA	NA	19.8	42.2	16.9
Yang	2020	61.5 (NA)	41	NA	37.2 \pm NA	71.5	73.4	74.9

BMI, body mass index; NA, not available; SD, standard deviation.

^aEstimated.

the rates reported in patients with cirrhosis of other etiologies.^{41,42} It is noteworthy that this rate (and its lower CI limit) lie above the 1.5% annual risk threshold usually accepted to recommend regular HCC surveillance.¹² We further carried out separate analyses for studies documenting the enrollment of patients in dedicated surveillance programs, and we found that screening raised the incidence rate of HCC to 4.62 per 100 PYs (95% CI, 2.77–7.72). On the basis of these results, the current meta-analysis strongly supports the implementation of regular screening programs for patients with NAFLD-related cirrhosis.

The novelty of the present meta-analysis revolves around patients with non-cirrhotic NAFLD, who are, in daily clinical care, commonly deemed to be at a higher risk of developing HCC in comparison with patients with chronic liver diseases of other etiologies. In this regard, the current results challenge this assumption, because we found a pooled incidence rate for HCC of 0.03 per 100 PYs (95% CI, 0.01–0.07) among patients with non-cirrhotic NAFLD. Although it is not based on the same measure of association, this finding contrasts with an interesting study by Piscaglia et al,⁴³ who documented that nearly 50% of NAFLD-associated HCCs arise within non-cirrhotic liver parenchyma. Although our estimate of the incidence of HCC in patients with non-cirrhotic

NAFLD may have been pushed toward the null because of the lack of screening in real-life clinical care, one may debate whether the study by Piscaglia et al was not prone to some selection bias that may have contributed to reveal a markedly elevated proportion of HCC in non-cirrhotic livers.⁴³ Of note, the pooled incidence rate of 0.03 per 100 PYs in our study was a result from the recruitment of a broad-spectrum disease (from simple steatosis forms to non-cirrhotic steatohepatitis and eventually early fibrosis) into a single category. The specific estimation of incidence rates of HCC at distinct pre-cirrhotic NAFLD stages could not be assessed, and this limitation calls for further research in these categories of patients.

Most of the results of the current meta-analysis are characterized by a high heterogeneity, likely because of the clinical variability of the individual studies included herein (for instance in terms of the methods used to define NAFLD, the strategy used to diagnose HCC, or the health care setting in which patients were clinically assessed). More importantly, such heterogeneity may also reflect the remarkable biological diversity of the pathogenesis of NAFLD at stages earlier than cirrhosis. This observation deserves a few comments. First, although debatable,⁴⁴ it is likely that the variability in the risk of developing HCC in non-cirrhotic patients may be




Figure 2. Meta-analyses of incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease, as depicted by forest plots. Each square represents the effect estimate of a study, along with its 95% confidence interval. Surface of the square summarizes the weight of that individual study in the meta-analysis. Vertical dashed line depicts the pooled effect estimate. (A) Studies that included at least some patients with cirrhosis. (B) Studies that included only patients with cirrhosis. (C) Studies that included patients with cirrhosis who were enrolled in a screening program. (D) Studies that included patients who did not undergo regular surveillance. (E) Pooled incidence rate in non-cirrhotic patients. CI, confidence interval; HCC, hepatocellular carcinoma.




Figure 3. Meta-regression analyses, as depicted by bubble plots, looking at impact of various sources of heterogeneity (x-axis) on calculated effect sizes (y-axis). (A) Duration of inclusion, (B) age of study population, (C) MELD score, (D) alanine aminotransferase levels, (E) percentage of males, (F) percentage of patients with diabetes, (G) aspartate aminotransferase levels, (H) platelet levels, (I) sex of study population, (J) body-mass index, (K) percentage of patients with hypertension, and (L) percentage of patients with dyslipidemia.

ascribable to the presence and the extent of hepatic inflammation and fibrosis rather than to the severity of liver steatosis.⁴⁵ Second, one may speculate on the existence of potential additional risk factors that would contribute to promoting hepatocarcinogenesis in those patients. One such risk factor could be exaggerated gut leakiness, where translocation of bacterial debris and other toxic products from the gut lumen to the portal circulation (for instance, during repeated bouts of spontaneous bacterial peritonitis) may promote liver inflammation and carcinogenesis via the engagement of innate immunity receptors by damage- and/or pathogen-associated molecular patterns.⁴⁶ Taken together, these data reinforce the idea that the “host condition” is not sufficient to trigger carcinogenesis, but that such host condition could rather be disrupted on exposure to specific risk factors. Notably, whereas some authors have proposed to take into account variables such as the PNPLA3 rs738409 C>G gene polymorphism,^{47,48} the impact of additional genetic or environmental factors and the gut microbiome could not be assessed in the current meta-analysis.

Another important aspect of the current work regards tumor surveillance. Although screening for HCC is effective at identifying HCC (potentially at an early, curable stage) as evidenced by the current results, biannual evaluation is difficult to implement.⁴⁹ Even in high-income countries, it has been shown that up to two-thirds of patients do not benefit from adequate biannual screenings,⁵⁰ putting them at risk of developing HCC during exaggeratedly prolonged intervals. Moreover, evidence indicates that screening programs carry an economic burden on the community,⁵¹ and that regular surveillance comes at an emotional cost for patients.^{52,53} Therefore, the World Health Organization recommendations state that cancer screening strategies should be both cost-effective and targeted toward very well-defined populations to minimize false-positive testing and avoiding psychological harm from such a public health policy.⁵⁴ On the basis of the currently assessed evidence, it could be assumed that our estimation of the incidence rate of HCC in non-cirrhotic livers of 0.03 per 100 PYs (95% CI, 0.01–0.07) does not support HCC screening in non-cirrhotic patients. This incidence reflected the rate of HCC among a heterogeneous group of patients, including those with simple steatosis and different degrees of fibrosis. This is of utmost relevance considering that those patients with more advanced fibrosis have been suggested to be at higher risk of HCC.⁵⁵ In addition, it is important to remember that our study aimed to establish the current incidence of HCC in these populations and not to suggest the benefits of a screening program for HCC. The incidence of HCC in specific populations is key for such an assessment, but it has to incorporate the data about life expectancy and competing risk of death posed by severe comorbidities (cardiovascular disease and non-liver cancer) as well as cost.

There are several strengths to our systematic review and meta-analysis. Indeed, it provides a comprehensive,

up-to-date assessment of currently available evidence. Nevertheless, the current results, although heterogeneous, challenge a dogma whereby patients with NAFLD, even at early disease stages, may be particularly prone to HCC and point out that there is no strong evidence until now to support the screening of patients with non-cirrhotic NAFLD. Specifically, this is an attempt to report distinct estimates of the incidence of HCC in various sub-populations of patients with NAFLD by meta-analysis. Finally, we were cautious in including only those studies clearly identifying NAFLD cases, and we excluded studies with doubtful diagnoses (eg, non-A, non-B hepatitis).

Our study also has some limitations. First, we could not gather quantitative information on the risk of HCC in non-cirrhotic patients with simple nonalcoholic fatty liver, NASH, or F1–F2 liver fibrosis from the current literature. Second, we performed sensitivity analyses looking at the impact of tumor screening only on the basis of those studies that clearly stated whether patients were adhering (or not) to a dedicated screening program. Therefore, we could not use studies that did not evaluate tumor surveillance. Third, despite investigating heterogeneity through various approaches, we did not obtain homogenous estimates of the incidence in the studied populations. Finally, because of the study design, we could not directly assess the impact of factors (such as metabolic risk factors or sex) beyond meta-regression.

In conclusion, this meta-analysis of observational studies provides pooled estimates of the incidence of HCC in patients with NAFLD. Even with high heterogeneity, our results support that HCC surveillance is beneficial in patients with NAFLD-related liver cirrhosis. By highlighting the scarcity of evidence on the value of screening for HCC in patients with non-cirrhotic NAFLD, the current systematic review should be used as the rationale for the design of a new risk-scoring tool (such as, by analogy, the PAGE-B score for patients with chronic hepatitis B⁵⁶). If shown accurate, such a tool would help in the tailoring of personalized surveillance programs for patients with NAFLD.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Clinical Gastroenterology and Hepatology* at www.cghjournal.org, and at <https://doi.org/10.1016/j.cgh.2021.05.002>.

References

1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016;64:73–84.
2. Bertot LC, Adams LA. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. *Expert Rev Gastroenterol Hepatol* 2019;13:179–187.

3. Pinero F, Costa P, Boteon YL, et al. A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. *Clin Res Hepatol Gastroenterol* 2018;42:443–452.
4. Tokushige K, Hyogo H, Nakajima T, et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. *J Gastroenterol* 2016;51:586–596.
5. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. *J Hepatol* 2018;69:896–904.
6. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. *Clin Gastroenterol Hepatol* 2019;17:748–755 e3.
7. Villanueva A. Hepatocellular carcinoma. *N Engl J Med* 2019;380:1450–1462.
8. Loomba R, Lim JK, Patton H, et al. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. *Gastroenterology* 2020.
9. Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2011;9:428–433, quiz e50.
10. Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. *Hepatology* 2012;55:1809–1819.
11. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. *Hepatology* 2011;53:1020–1022.
12. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018;68:723–750.
13. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2018;69:182–236.
14. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. *Clin Gastroenterol Hepatol* 2012;10:1342–1359 e2.
15. Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. *Aliment Pharmacol Ther* 2018;48:696–703.
16. Reig M, Gambato M, Man NK, et al. Should patients with NAFLD/NASH be surveyed for HCC? *Transplantation* 2019;103:39–44.
17. Available at: <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>. Accessed May 1, 2019.
18. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* 2005;5:13.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177–188.
20. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–560.
21. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. *Ann Intern Med* 1997;127:820–826.
22. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 2005;129:113–121.
23. Arase Y, Kobayashi M, Suzuki F, et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. *Hepatol Res* 2012;42:264–272.
24. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Hepatology* 2010;51:1972–1978.
25. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. *Hepatology* 2011;54:1208–1216.
26. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006;44:865–873.
27. Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. *J Gastroenterol Hepatol* 2009;24:248–254.
28. Hsiang JC, Bai WW, Raos Z, et al. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand. *Intern Med J* 2015;45:160–169.
29. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. *Hepatology* 2003;38:420–427.
30. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. *Gastroenterology* 2018;155:1828–1837 e2.
31. Kawamura Y, Arase Y, Ikeda K, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. *Am J Gastroenterol* 2012;107:253–261.
32. Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. *J Hepatol* 2017;45:345–353.
33. Kodama K, Tokushige K, Hashimoto E, et al. Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. *Alcohol Clin Exp Res* 2013;37(Suppl 1):E247–E252.
34. Lee TY, Wu JC, Yu SH, et al. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. *Int J Cancer* 2017;141:1307–1314.
35. Marot A, Henrion J, Knebel JF, et al. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: an observational study. *PLoS One* 2017;12:e0186715.
36. Onnerhag K, Nilsson PM, Lindgren S. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. *Scand J Gastroenterol* 2014;49:1111–1118.
37. Alexander M, Loomis AK, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study

- of 18 million patients in four European cohorts. *BMC Med* 2019;17:95.
38. Yang JD, Ahmed F, Mara KC, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. *Hepatology* 2020; 71:907–916.
 39. Hashimoto E, Yatsuji S, Tobar M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *J Gastroenterol* 2009;44(Suppl 19):89–95.
 40. Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. *Hepatology* 2006;43:682–689.
 41. Waziry R, Grebely J, Amin J, et al. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014). *J Hepatol* 2016;65:1086–1093.
 42. Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. *J Hepatol* 2017;67:1204–1212.
 43. Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. *Hepatology* 2016; 63:827–838.
 44. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. *Hepatology* 2009;49:851–859.
 45. Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. *NPJ Precis Oncol* 2018;2:6.
 46. Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. *Nat Rev Gastroenterol Hepatol* 2017;14:527–539.
 47. Grimaudo S, Pipitone RM, Pennisi G, et al. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2020;18:935–944.e3.
 48. Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. *J Hepatol* 2014;61:75–81.
 49. Singal AG, Murphy CC. Hepatocellular carcinoma surveillance: an effective but complex process. *Gastroenterology* 2019; 156:1215.
 50. Majeed A, Roberts SK, Kemp W. Re: no association between screening for hepatocellular carcinoma and reduced cancer-related mortality in patients with cirrhosis. *Gastroenterology* 2019;156:1217.
 51. Ruggeri M. Hepatocellular carcinoma: cost-effectiveness of screening—a systematic review. *Risk Manag Healthc Policy* 2012;5:49–54.
 52. Rich NE, Parikh ND, Singal AG. Overdiagnosis: an understudied issue in hepatocellular carcinoma surveillance. *Semin Liver Dis* 2017;37:296–304.
 53. Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. *Hepatology* 2017;65:1196–1205.
 54. World Health Organization. Cancer control, knowledge into action, WHO guide for effective programmes: early detection; 2007.
 55. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* 2020.
 56. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. *J Hepatol* 2016;64:800–806.

Reprint requests

Address requests for reprints to: Maria Reig, MD, PhD, BCLC group, Liver Unit, Hospital Clinic of Barcelona, Carrer de Villarroel, 170, 08036 Barcelona, Spain. e-mail: mreig1@clinic.cat; fax: +34 93 2279234; or Christian Toso, MD, PhD, Division of Abdominal Surgery, Department of Surgery, Geneva University Hospitals and Faculty of Medicine, 4 rue Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland; fax: +41223729506; e-mail: christian.toso@hcuge.ch.

CRedit Authorship Contributions

Lorenzo A. Orci (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Writing – original draft: Lead)
 Marco Sanduzzi-Zamparelli (Conceptualization: Equal; Data curation: Equal; Formal analysis: Lead; Writing – original draft: Lead)
 Berta Caballol (Methodology: Equal)
 Victor Sapena (Data curation: Equal; Formal analysis: Lead; Methodology: Lead)
 Nicola Colucci (Writing – review & editing: Supporting)
 Ferran Torres (Conceptualization: Equal; Formal analysis: Equal; Methodology: Equal)
 Jordi Bruix (Conceptualization: Equal; Writing – review & editing: Lead)
 Maria Reig, MD, PhD (Conceptualization: Lead; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Lead)
 Christian Toso (Conceptualization: Lead; Writing – original draft: Equal; Writing – review & editing: Lead)

Conflicts of interest

These authors disclose the following: MSZ received speaker fees from Bayer and travel grants from Bayer, BTG, and Eisai. BC received travel grants from Bayer. VS received travel grants from Bayer. JB has consulted for Arqule, Bayer-Schering Pharma, Novartis, BMS, BTG- Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, MSD, Sirtex, Ipsen, Astra-Med-immune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano, and Sanofi and received research/educational grants from Bayer and lecture fees from Bayer-Schering Pharma, BTG-Biocompatibles, Eisai, Terumo, Sirtex, and Ipsen. MR received consultancy fees from Bayer, BMS, Roche, Ipsen, AstraZeneca, and Lilly, lecture fees from Bayer, BMS, Gilead, ROCHE and Lilly, and research grants from Bayer and Ipsen. The remaining authors disclose no conflicts.

Funding

Supported by grants from the Swiss National Science Foundation (grants no. 323530–151477 and PP00P3_139021) and the Geneva Cancer League (grant no. 1509). MSZ was supported by Ajuts per a la Iniciació a la Recerca 2019 from the Societat Catalana de Digestologia (SCD) and Instituto de Salud Carlos III (grant no. FI19/00222). JB was supported by Instituto de Salud Carlos III (grant no. PI18/00768), AECC (grant no. PI044031), and WCR/AICR (grant no. 16-0026). MR was supported by Instituto de Salud Carlos III (grants no. PI15/00145 and PI18/0358). CIBERehd is funded by Instituto de Salud Carlos III. The funding sources had no role in the design, conduct, or reporting of the study or in the decision to publish the manuscript.

Central n = 476


(naflid:ab,ti or nbnc:ab,ti or nafl:ab,ti or (('non alcoholic' or 'non-alcoholic' or 'nonalcoholic') near/1 ('fatty liver disease' or 'fatty liver' or 'steatosis' or 'steatohepatitis' or 'steato-hepatitis' or 'steato hepatitis')):ab,ti or 'non viral hepatitis':ab,ti or 'non-viral hepatitis':ab,ti or 'non b non c':ab,ti or 'non-b non-c':ab,ti or 'fatty liver':-ab,ti or 'nash':ab,ti or 'steato-hepatitis':ab,ti or 'steato-hepatitis':ab,ti or 'liver steatosis':ab,ti or 'steatosis':ab,ti or 'metabolic syndrome':ab,ti or 'liver fat infiltration':ab,ti) and (((('hepatic' or 'liver cell' or 'hepatic cell' or 'hepatocellular' or 'liver') near/1 (carcinoma or cancer)):ab,ti or hepatocarcinoma:ab,ti or hepatoma:ab,ti or 'malignant hepatoma':ab,ti or 'hcc':ab,ti or 'carcinoma of the liver':ab,ti)

References

1. Abe H, Yoshizawa K, Kitahara T, et al. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. *J Gastroenterol* 2008;43:967–974.
2. Amarapurkar DN, Dharod M, Gautam S, et al. Risk of development of hepatocellular carcinoma in patients with NASH-related cirrhosis. *Trop Gastroenterol* 2013;34:159–163.
3. Anagnostopoulos GK, Arvanitidis D, Tsiakos S, et al. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? *J Clin Gastroenterol* 2003;37:88–89.
4. Archambeaud I, Auble H, Nahon P, et al. Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity. *Liver Int* 2015;35:1872–1876.
5. Atchison E, Gridley G, Carreon D, et al. Risk of cancer in a large cohort of U.S. veterans with diabetes. *Int J Cancer* 2017;128:635–643.
6. Borena W, Strohmaier S, Lukanova A, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. *Int J Cancer* 2012;131:193–200.
7. Cho EJ, Kwack MS, Jang ES, et al. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. *Digestion* 2011;84(Suppl 1):17–22.
8. Cotrim HP, Oliveira CP, Coelho HS, et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey. *Clinics (Sao Paulo, Brazil)* 2016;71:281–284.
9. David D, Raghavendran A, Goel A, et al. Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India. *Indian Journal of Gastroenterology* 2017;36:373–379.
10. Dyson J, Jaques B, Chattopadhyay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. *J Hepatol* 2014;60:110–117.
11. Ertle J, Dechene A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. *Int J Cancer* 2011;128:2436–2443.
12. Feng X, Wang G, Li N, et al. The association between fasting blood glucose and the risk of primary liver cancer in Chinese males: a population-based prospective study. *Br J Cancer* 2017;117:1405–1411.
13. Guzman G, Brunt EM, Petrovic LM, et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? *Arch Pathol Lab Med* 2008;132:1761–1766.
14. Hashimoto E, Tani M, Kaneda H, et al. Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis. *Alcohol Clin Exp Res* 2004;28:164s–168s.
15. Hashizume H, Sato K, Takagi H, et al. Primary liver cancers with nonalcoholic steatohepatitis. *Eur J Gastroenterol Hepatol* 2007;19:827–834.
16. Huckle F, Sieghart W, Schoniger-Hekele M, et al. Clinical characteristics of patients with hepatocellular carcinoma in Austria: is there a need for a structured screening program? *Wiener Klinische Wochenschrift* 2011;123:542–551.
17. Imura S, Shimada M, Utsunomiya T, et al. Clinicopathological characteristics of patients with non-B non-C hepatocellular carcinoma: a special reference to metabolic syndrome. *Hepato-gastroenterology* 2014;61:129–135.
18. Jain D, Nayak NC, Saigal S. Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients. *Eur J Gastroenterol Hepatol* 2012;24:840–848.
19. Kutsenko A, Ladenheim MR, Kim N, et al. Increased prevalence of metabolic risk factors in Asian Americans with hepatocellular carcinoma. *J Clin Gastroenterol* 2017;51:384–390.
20. Leung C, Yeoh S, Patrick D, et al. Hepatocellular carcinoma can occur in non-alcoholic fatty liver disease without cirrhosis. *J Gastroenterol Hepatol* 2013;28:76.
21. Leung C, Yeoh SW, Patrick D, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. *World J Gastroenterol* 2015;21:1189–1196.
22. Liu YL, Patman G, Leathart J, et al. Carriage of PNPLA3 I148M is associated with an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. *J Hepatol* 2013;58:S516.
23. Mair RD, Valenzuela A, Ha NB, et al. Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. *Clin Gastroenterol Hepatol* 2012;10:1412–1417.
24. Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. *Hepatology* 2002;36:1349–1354.
25. Masuzaki R, Karp SJ, Omata M. NAFLD as a risk factor for HCC: new rules of engagement? *Hepatol Int* 2016;10:533–534.
26. Mittal S, Sada Y, El-Serag H, et al. Surveillance and outcomes in non-alcoholic fatty liver disease related hepatocellular carcinoma in veteran affairs (VA) population. *Gastroenterology* 2014;146:S991–S992.
27. Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. *Clin Gastroenterol Hepatol* 2015;13:594–601.e1.
28. Mohamad B, Shah V, Onyshchenko M, et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. *Hepatol Int* 2016;10:632–639.
29. Mohsen W, Rodov M, Prakoso E, et al. Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. *World J Gastroenterol* 2017;23:2763–2770.

30. Mukherjee PS, Vishnubhatla S, Amarapurkar DN, et al. Etiology and mode of presentation of chronic liver diseases in India: a multi centric study. *PLoS One* 2017;12:e0187033.
31. Nderitu P, Bosco C, Garmo H, et al. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort. *Int J Cancer* 2017;141:1148–1160.
32. Perumpail RB, Wong RJ, Ahmed A, et al. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. *Dig Dis Sci* 2015;60:3142–3148.
33. Petrick JL, Freedman ND, Demuth J, et al. Obesity, diabetes, serum glucose, and risk of primary liver cancer by birth cohort, race/ethnicity, and sex: multiphasic health checkup study. *Cancer Epidemiol* 2016;42:140–146.
34. Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. *Hepatology* 2016;63:827–838.
35. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. *Hepatology* 2002;35:1485–1493.
36. Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. *Hepatology* 2012;55:1809–1819.
37. Rodríguez de Lope C, Reig M, Matilla A, et al. Clinical characteristics of hepatocellular carcinoma in Spain: comparison with the 2008–2009 period and analysis of the causes of diagnosis out of screening programs—analysis of 686 cases in 73 centers. *Medicina Clinica* 2017;149:61–71.
38. Schutte K, Kipper M, Kahl S, et al. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. *Digestion* 2013;87:147–159.
39. Schutte K, Schulz C, Poranzke J, et al. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. *BMC Gastroenterology* 2014;14:117.
40. Seko Y, Sumida Y, Tanaka S, et al. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression. *Hepatology Research* 2017;47:1083–1092.
41. Seko Y, Sumida Y, Tanaka S, et al. Progression and HCC in Japanese patients with NAFLD. *Hepatology International* 2016;10:S438.
42. Stepanova M, Rafiq N, Makhlof H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). *Dig Dis Sci* 2013;58:3017–3023.
43. Sun LM, Lin MC, Lin CL, et al. Nonalcoholic cirrhosis increased risk of digestive tract malignancies: a population-based cohort study. *Medicine* 2015;94:e2080.
44. Takamatsu S, Noguchi N, Kudoh A, et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. *Hepato-gastroenterology* 2008;55:609–614.
45. Takuma Y, Nouse K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. *World J Gastroenterol* 2010;16:1436–1441.
46. Tateishi R, Okanou T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. *J Gastroenterol* 2015;50:350–360.
47. Than NN, Ghazanfar A, Hodson J, et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. *QJM* 2017;110:73–81.
48. Tokushige K, Hashimoto E, Horie Y, et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. *J Gastroenterol* 2011;46:1230–1237.
49. Tokushige K, Hashimoto E, Yatsuji S, et al. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. *J Gastroenterol* 2010;45:960–967.
50. Turati F, Talamini R, Pelucchi C, et al. Metabolic syndrome and hepatocellular carcinoma risk. *Br J Cancer* 2013;108:222–228.
51. van Meer S, van Erpecum KJ, Sprengers D, et al. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. *Eur J Gastroenterol Hepatol* 2016;28:352–359.
52. van Meer S, van Erpecum KJ, Sprengers D, et al. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. *Eur J Gastroenterol Hepatol* 2016;28:955–962.
53. Weinmann A, Alt Y, Koch S, et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. *BMC Cancer* 2015;15.
54. Weinmann A, Koch S, Niederle IM, et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. *J Clin Gastroenterol* 2014;48:279–289.
55. Welzel TM, Graubard BI, Davila JA, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States. *Cancer Res* 2011;71.
56. Yang JD, Ahmed Mohammed H, Harmsen WS, et al. Recent trends in the epidemiology of hepatocellular carcinoma in Olmsted County, Minnesota: a US population-based study. *J Clin Gastroenterol* 2017;51:742–748.
57. Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. *Clin Gastroenterol Hepatol* 2011;9:617–623.e1.
58. Yang JD, Kim B, Sanderson SO, et al. Hepatocellular carcinoma in Olmsted county, Minnesota, 1976–2008. *Mayo Clinic Proc* 2012;87:9–16.
59. Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2011;9:428–433.
60. Yoshioka Y, Hashimoto E, Yatsuji S, et al. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. *J Gastroenterol* 2004;39:1215–1218.
61. Younossi Z, Otgonsuren M, Henry L, et al. Increasing association of non-alcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma in the United States: data from surveillance, epidemiology and end results (SEER)-medicare registries (2004–2009). *J Hepatol* 2015;62:S209.

62. Yu MW, Lin CL, Liu CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. *Gastroenterology* 2017;153:1006–1017.e5.
63. Zen Y, Katayanagi K, Tsuneyama K, et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. *Pathol Int* 2001;51:127–131.
64. Liu ZQ, Suo C, Mao XH, et al. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017. *Cancer* 2020;126:2267–2278.
65. Sangaramoorthy M, Yang J, DeRouen MC, et al. Disparities in hepatocellular carcinoma incidence in California: an update. *Cancer Epidemiol Biomarkers Prev* 2020;29:79–87.
66. Tobari M, Hashimoto E, Taniai M, et al. The characteristics and risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis. *Hepatology* 2019;70:1344A-A.
67. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. *Gastroenterology* 2002;123:134–140.
68. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. *Hepatology* 2009;49:851–859.
69. Schulz PO, Ferreira FG, Nascimento Mde F, et al. Association of nonalcoholic fatty liver disease and liver cancer. *World J Gastroenterol* 2015;21:913–918.
70. Beste LA, Leipertz SL, Green PK, et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. *Gastroenterology* 2015;149:1471–1482 e5.
71. Hernandez-Alejandro R, Croome KP, Drage M, et al. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. *World J Gastroenterol* 2012;18:4145–4149.



Supplementary Figure 1. Funnel plot.

Supplementary Table 1. Reason for Excluding 71 Out of the 89 Selected Articles

First author	Reason for exclusion
Abe ¹	Non-B, non-C HCC, cryptogenic cirrhosis
Amarapurkar ²	Inadequate design
Anagnostopoulos ³	Inadequate design
Archambeaud ⁴	Not clearly NAFLD-related
Atchinson ⁵	Metabolic syndrome, diabetes, not clearly NAFLD-related
Beste ⁷⁰	More recent estimates in the same veterans population are available
Borena ⁶	Metabolic syndrome, diabetes, not clearly NAFLD-related
Cho ⁷	Inadequate design
Cotrim ⁸	Inadequate design
David ⁹	Inadequate design, looks at prevalence of given risk factors of HCC in patients with NAFLD
Dyson ¹⁰	Metabolic syndrome, diabetes, not clearly NAFLD-related
Ertle ¹¹	Inadequate design, cross-sectional survey and comparison of patients' characteristics
Feng ¹²	Metabolic syndrome, diabetes, not clearly NAFLD-related
Guzman ¹³	Inadequate design, identification and assessment of three cases
Hashimoto ¹⁴	Inadequate design, possible population overlap with other studies
Hashizume ¹⁵	Inadequate design, description of selected cases of NAFLD-HCC and NAFLD-cholangiocarcinoma
Hernandez-Alejandro ⁷¹	Inadequate design
Hucke ¹⁶	Inadequate design, characteristics of patients with HCC in Austria (not particularly NAFLD-oriented)
Imura ¹⁷	Metabolic syndrome, diabetes, not clearly NAFLD-related
Jain ¹⁸	Metabolic syndrome, diabetes, not clearly NAFLD-related
Kutsenko ¹⁹	Metabolic syndrome, diabetes, not clearly NAFLD-related
Leung ²⁰	Inadequate design
Leung ²¹	Inadequate design, clinical characteristics of 54 patients with NAFLD-HCC
Liu ²²	Association between a given genotype and HCC
Mair ²³	Not really NAFLD-oriented
Marrero ²⁴	Inadequate design, point prevalence of given etiologies among US patients with NASH
Masuzaki ²⁵	Inadequate design, opinion/review
Mittal ²⁶	More recent estimates in the same veterans population are available
Mittal ²⁷	More recent estimates in the same veterans population are available
Mohamad ²⁸	Inadequate design, comparison of NAFLD-related HCC patients with or without underlying cirrhosis.
Mohsen ²⁹	Inadequate design
Mukherjee ³⁰	Metabolic syndrome, diabetes, not clearly NAFLD-related
Nderitu ³¹	Metabolic syndrome, diabetes, not clearly NAFLD-related
Perumpail ³²	Metabolic syndrome, diabetes, not clearly NAFLD-related
Petrick ³³	Metabolic syndrome, diabetes, not clearly NAFLD-related
Piscaglia ³⁴	Inadequate design, comparison of NAFLD-related and HCV-related HCC patients, looking at tumor morphology and survival
Ratzu ³⁵	Non-B, non-C HCC, cryptogenic cirrhosis
Reddy ³⁶	Inadequate design, evaluates treatment response rather than describing incidence
Rodríguez de Lope ³⁷	Inadequate design, comparison of patients' characteristics rather than interest in the rate of incidence

Supplementary Table 1. Continued

First author	Reason for exclusion
Schutte ³⁸	Metabolic syndrome, diabetes, not clearly NAFLD-related
Schutte ³⁹	Metabolic syndrome, diabetes, not clearly NAFLD-related
Seko ⁴⁰	Association between a given genotype and HCC
Seko ⁴¹	Association between a given genotype and HCC
Stepanova ⁴²	Inadequate design, looks at survival of patients with NASH or non-inflammatory NAFLD
Sun ⁴³	Inadequate design looks at nonalcoholic cirrhosis as a risk for digestive tract malignancies, but in the group of cirrhosis included HBV-HCV patients. The whole NAC group (non-OH cirrhosis, including viral etiology), used to calculate HCC and other tumors' incidence rates.
Takamatsu ⁴⁴	Metabolic syndrome, diabetes, not clearly NAFLD-related
Takuma ⁴⁵	Inadequate design
Tateishi ⁴⁶	Inadequate design, comparison of patients' characteristics rather than interest in the rate of incidence
Than ⁴⁷	Inadequate design
Tokushige ⁴⁸	Inadequate design
Tokushige ⁴⁹	Inadequate design
Turati ⁵⁰	Metabolic syndrome, diabetes, not clearly NAFLD-related
van Meer ⁵¹	Inadequate design, group aggregation makes it impossible to extract relevant data for the purpose of the current systematic review
van Meer ⁵²	Inadequate design, group aggregation makes it impossible to extract relevant data for the purpose of the current systematic review
Weinmann ⁵³	Inadequate design, compares NAFLD-related HCC with HCC from other etiologies, looking at survival and other outcomes. Does not look at the incidence
Weinmann ⁵⁴	Metabolic syndrome, diabetes, not clearly NAFLD-related
Welzel ⁵⁵	Metabolic syndrome, diabetes, not clearly NAFLD-related
Yang ⁵⁶	Metabolic syndrome, diabetes, not clearly NAFLD-related
Yang ⁵⁷	Metabolic syndrome, diabetes, not clearly NAFLD-related
Yang ⁵⁸	Population overlap with another study (Yang et al, 2020)
Yasui ⁵⁹	Inadequate design, looks at characteristics of patients with NAFLD-HCC
Yoshioka ⁶⁰	Full-text should not have been assessed because this is a case report, but quick abstract reading among thousands leads to full-text scrutiny.
Younossi ⁶¹	Inadequate design. Assesses proportion of HCC among patients with different types of liver disease.
Yu ⁶²	Metabolic syndrome, diabetes, not clearly NAFLD-related
Zen ⁶³	Inadequate design, wrongfully selected abstract
Liu ⁶⁴	HCC incidence not reported according to etiology or criteria in present study
Sangaramoorthy ⁶⁵	HCC incidence not reported according to etiology or criteria in present study
Tobari ⁶⁶	HCC incidence not reported according to etiology or criteria in present study
Bugianesi ⁶⁷	NAFLD not clearly defined
Paradis ⁶⁸	NAFLD not clearly defined
Schulz ⁶⁹	NAFLD not clearly defined

HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NAC, N-acetylcysteine.

Supplementary Table 2. NAFLD Definition, Presence of Simple Steatosis, NASH, and Cirrhosis Among the Included Studies

First author	Year of publication	NAFLD/NASH definition	Total number of NAFLD (NAFLD, NASH, or both)	Patients with NAFLD non-NASH (%)	Patients with NASH (%)	NAFLD patients with cirrhosis (%)
Hui	2003	Histology	23	NA	100	100
Adams	2005	Histology and/or ultrasound and/or CT scan and/or MRI	420	88.3	11.7	NA
Ekstedt	2006	NA	88	19.3	80.7	4.5
Hashimoto	2009	Histology	382	NA	100	35.8
Yatsuji	2009	Histology	68	NA	100	100
Ascha	2010	Histology or metabolic syndrome without alcohol or viral hepatitis	195	0	0	100
Bhala	2011	Histology	247	NA	NA	52.2
Arase	2012	US	1600	NA	NA	NA
Kawamura	2012	US	6508	NA	NA	NA
Kodama	2013	Histology and absence of alcohol or viral hepatitis	72	NA	NA	100
Önnerhag	2014	Histology	36	61.1	38.9	25
Hsiang	2015	Histology or transient elastography or radiology	122	NA	NA	100
Kim	2017	US	8721	NA	NA	NA
Lee	2017	NA	18,080	NA	NA	NA
Marot	2017	Histology and/or absence of alcohol or viral hepatitis or other cause of liver disease	78	NA	NA	100
Kanwal	2018	Laboratory	296,707	NA	NA	0.5
Alexander	2019	NA	136,703	NA	NA	0
Yang	2020	NA	354	0	100	100

CT, computed tomography; MRI, magnetic resonance imaging; NA, not available; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; US, ultrasound.

Supplementary Table 3. Quality of Included Studies

Study	Barcelona	Geneva	Consensus (quality)
Hui	1	1	1
Adams	0	0	0
Ekstedt	1	0	1
Hashimoto	1	1	1
Yatsuji	1	1	1
Ascha	0	0	0
Bhala	0	0	0
Arase	2	2	2
Kawamura	1	1	1
Kodama	0	1	1
Önnerhag	0	0	0
Hsiang	0	1	1
Kim	1	1	1
Lee	1	1	1
Marot	1	1	1
Kanwal	1	1	1
Alexander	0	0	0
Yang	0	0	0

NOTE. On the basis of the National Institutes of Health Study Quality Assessment Tool, studies were given 0, 1, or 2 points, corresponding to low, moderate, and high risk of bias, respectively.

Supplementary Table 5. Output of Meta-regression Analyses

Variable ^a	Coefficient	<i>I</i> ²	τ^2	<i>P</i> value for heterogeneity
Duration of inclusion (y)	.6	92%	0.68	<.001
Age (y)	.049	87%	0.45	<.001
% of males	.3	87%	0.6	<.001
% of diabetics	.12	85%	0.51	<.001
Year of publication (≤ 2010 vs >2010)	.07	86%	0.42	<.001
MELD score	.2	90%	0.59	<.001
ALT (IU/L)	.18	88%	1.15	<.001
AST (IU/L)	.4	86%	1.37	<.001
Platelet count ($10^9/L$)	.3	90%	0.74	<.001

ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCC, hepatocellular carcinoma; MELD, Model for End-Stage Liver Disease.

^aAll meta-regressions are subject to data availability. Some values have been transformed from median to unify average values between studies.

Supplementary Table 4. Sensitivity Analyses

	No. of studies	Pooled incidence of HCC in NAFLD in cirrhotic patients per 100 person-years (95% CI)	<i>I</i> ²	τ^2	<i>P</i> value for heterogeneity
NAFLD diagnostic tool^a					
Combination	5	3.96 (3.09–5.06)	0%	0	.61
Lab test	1	1.06 (0.87–1.28)	—	—	—
Histology	4	1.36 (0.28–6.60)	93%	2.11	<.01
Epidemiologic design					
Retrospective	6	2.72 (1.62–4.58)	93%	0.34	<.01
Prospective	5	1.68 (0.50–5.62)	91%	1.53	<.01
Location					
Asia (Japan)	2	5.82 (2.09–15.1)	86%	0.44	<.01
USA	4	2.31 (1.13–4.72)	94%	0.44	<.01
Others	5	1.50 (0.57–3.93)	81%	0.88	<.01
Quality					
Good	4	2.75 (1.54–4.91)	72%	0.21	<.01
Fair	7	2.17 (0.95–4.94)	95%	1.03	<.01

HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver disease.

^aYang 2020, not available.

Supplementary Table 6. Leave-One-Out Analysis

Omitted study	Pooled effect (95% CI)	τ^2	I^2
Hui, 2003	2.54 (1.49–4.33)	0.62	93.2%
Adams, 2005	2.32 (1.31–4.13)	0.70	93.3%
Yatsuji, 2009	2.08 (1.27–3.40)	0.46	89.0%
Ascha, 2010	2.19 (1.23–3.91)	0.68	92.1%
Bhala, 2011	2.84 (1.77–4.56)	0.43	92.8%
Kodama, 2013	2.29 (1.26–4.14)	0.73	93.2%
Önnerhag, 2014	2.52 (1.43–4.44)	0.67	93.2%
Hsiang, 2015	2.22 (1.24–3.97)	0.70	92.8%
Marot, 2017	2.32 (1.28–4.22)	0.74	93.2%
Kanwal, 2018	2.68 (1.55–4.63)	0.59	83.0%
Yang, 2020	2.39 (1.31–4.37)	0.74	93.3%
Pooled estimate	2.39 (1.40–4.08)	0.64	93%

CI, confidence interval.